Tags

Type your tag names separated by a space and hit enter

Cannabinoid Receptors in Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance.
Handb Exp Pharmacol. 2017; 239:343-362.HE

Abstract

Cannabinoid receptors are fundamentally involved in all aspects of intestinal physiology, such as motility, secretion, and epithelial barrier function. They are part of a broader entity, the so-called endocannabinoid system which also includes their endocannabinoid ligands and the ligands' synthesizing/degrading enzymes. The system has a strong impact on the pathophysiology of the gastrointestinal tract and is believed to maintain homeostasis in the gut by controlling hypercontractility and by promoting regeneration after injury. For instance, genetic knockout of cannabinoid receptor 1 leads to inflammation and cancer of the intestines. Derivatives of Δ9-tetrahydrocannabinol, such as nabilone and dronabinol, activate cannabinoid receptors and have been introduced into the clinic to treat chemotherapy-induced emesis and loss of appetite; however, they may cause many psychotropic side effects. New drugs that interfere with endocannabinoid degradation to raise endocannabinoid levels circumvent this obstacle and could be used in the future to treat emesis, intestinal inflammation, and functional disorders associated with visceral hyperalgesia.

Authors+Show Affiliations

Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria.Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria.Zentrum für Endoskopie, Starnberg, Germany. martin.storr@med.uni-muenchen.de. Ludwig-Maximilians University Munich, Marchioninistr. 15, 81377, Munich, Germany. martin.storr@med.uni-muenchen.de.Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28161834

Citation

Taschler, Ulrike, et al. "Cannabinoid Receptors in Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance." Handbook of Experimental Pharmacology, vol. 239, 2017, pp. 343-362.
Taschler U, Hasenoehrl C, Storr M, et al. Cannabinoid Receptors in Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance. Handb Exp Pharmacol. 2017;239:343-362.
Taschler, U., Hasenoehrl, C., Storr, M., & Schicho, R. (2017). Cannabinoid Receptors in Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance. Handbook of Experimental Pharmacology, 239, 343-362. https://doi.org/10.1007/164_2016_105
Taschler U, et al. Cannabinoid Receptors in Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance. Handb Exp Pharmacol. 2017;239:343-362. PubMed PMID: 28161834.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabinoid Receptors in Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance. AU - Taschler,Ulrike, AU - Hasenoehrl,Carina, AU - Storr,Martin, AU - Schicho,Rudolf, PY - 2017/2/6/pubmed PY - 2017/10/17/medline PY - 2017/2/6/entrez KW - Cannabinoid receptors KW - Colon cancer KW - GPR55 KW - IBD KW - IBS KW - Intestinal inflammation KW - PPARα KW - TRPV1 SP - 343 EP - 362 JF - Handbook of experimental pharmacology JO - Handb Exp Pharmacol VL - 239 N2 - Cannabinoid receptors are fundamentally involved in all aspects of intestinal physiology, such as motility, secretion, and epithelial barrier function. They are part of a broader entity, the so-called endocannabinoid system which also includes their endocannabinoid ligands and the ligands' synthesizing/degrading enzymes. The system has a strong impact on the pathophysiology of the gastrointestinal tract and is believed to maintain homeostasis in the gut by controlling hypercontractility and by promoting regeneration after injury. For instance, genetic knockout of cannabinoid receptor 1 leads to inflammation and cancer of the intestines. Derivatives of Δ9-tetrahydrocannabinol, such as nabilone and dronabinol, activate cannabinoid receptors and have been introduced into the clinic to treat chemotherapy-induced emesis and loss of appetite; however, they may cause many psychotropic side effects. New drugs that interfere with endocannabinoid degradation to raise endocannabinoid levels circumvent this obstacle and could be used in the future to treat emesis, intestinal inflammation, and functional disorders associated with visceral hyperalgesia. SN - 0171-2004 UR - https://www.unboundmedicine.com/medline/citation/28161834/Cannabinoid_Receptors_in_Regulating_the_GI_Tract:_Experimental_Evidence_and_Therapeutic_Relevance_ L2 - https://dx.doi.org/10.1007/164_2016_105 DB - PRIME DP - Unbound Medicine ER -